Astellas Presents VEOZA™ Data at the International Menopause Conference
Astellas Pharma Inc. is excited to announce that VEOZA™ (fezolinetant), an innovative treatment for managing moderate to severe vasomotor symptoms (VMS) associated with menopause, will be showcased extensively at the International Menopause Society’s World Congress on Menopause. This congress, a significant event for discussing advancements in menopause care and treatments, is anticipated to provide valuable insights into women's health.
Impactful Presentations at the World Congress
The congress will feature a total of six presentations from Astellas, comprising four oral talks and two poster sessions. These presentations are essential for revealing critical data on how VEOZA™ impacts symptoms such as hot flashes and night sweats, which many women experience during menopause.
Focus on Patient-Reported Outcomes
Two key oral presentations from the SKYLIGHT studies will emphasize patient-reported outcomes regarding sleep quality and workplace productivity. The insights from these studies aim to better understand how VEOZA™ can potentially improve quality of life for women experiencing VMS. Presentations will occur during the Menopause New Treatments sessions, scheduled for October 21.
Comprehensive Data Analysis
Additionally, data from the DAYLIGHT study will be discussed, which investigates the effects of VEOZA™ in women who are not suitable for hormone therapy. This exploration is crucial in offering alternative treatment options for a diverse group of women struggling with VMS.
Understanding the Significance of VEOZA™
Astellas's leadership, including Marci English and Emad Siddiqui, expresses their commitment to advancing treatment options for menopausal symptoms. They highlight that the knowledge gained from the presentations will significantly contribute to the understanding of VMS and women's preferences for managing these symptoms.
Details of Specific Presentations
The presentations set to occur at the congress include:
- Findings from the SKYLIGHT 1 and 2 studies, focusing on the impact of VEOZA™ on sleep and productivity at work.
- Daylight study results emphasizing quality of life improvements in women unsuitable for traditional hormone therapies.
- Poster discussions include data indicating no link between VEOZA™ treatment and the occurrence of malignant neoplasms.
- Insights into the new HIGHLIGHT study, designed to evaluate VEOZA™ for women undergoing breast cancer treatment.
About VEOZA™ and Its Mechanism
VEOZA™ is a non-hormonal treatment aimed at addressing menopause-related VMS. It operates by targeting neurokinin 3 (NK3) receptors in the brain, effectively modulating neuronal activity in the hypothalamus—the body’s temperature regulation center to reduce the frequency and severity of hot flashes. With VEOZA™, women now have a promising non-hormonal option for managing their symptoms.
About Astellas Pharma
Astellas Pharma Inc. engages in research and development efforts to provide innovative healthcare solutions tailored to patients’ needs. Operating in over 70 countries, Astellas continuously works to address significant unmet medical needs using its Focus Area Approach, which is committed to delivering new drugs and healthcare solutions that leverage the latest scientific advancements.
Frequently Asked Questions
What is VEOZA™?
VEOZA™ (fezolinetant) is a non-hormonal treatment for moderate to severe vasomotor symptoms related to menopause.
Where will Astellas present VEOZA™ data?
Astellas will feature VEOZA™ at the International Menopause Society's World Congress on Menopause.
What topics will Astellas cover in its presentations?
Topics include patient-reported outcomes on sleep and productivity, quality of life for women unsuitable for hormone therapy, and trial designs for ongoing studies involving fezolinetant.
Is VEOZA™ safe?
Clinical data presented will include safety and efficacy analyses, reflecting its benefits for managing menopausal symptoms.
Who can benefit from VEOZA™?
VEOZA™ is designed for women suffering from moderate to severe vasomotor symptoms during menopause, especially those seeking non-hormonal treatment options.
